Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

MyNCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 1
2013 3
2014 2
2015 4
2016 1
2017 3
2018 6
2019 5
2020 1
Text availability
Article attribute
Article type
Publication date

Search Results

23 results
Results by year
Filters applied: . Clear all
Page 1
Recent advances in understanding and treating immunoglobulin light chain amyloidosis.
Badar T, et al. F1000Res 2018 - Review. PMID 30228867 Free PMC article.
Early referral to a specialized center with expertise in management of AL amyloidosis is always recommended. The availability of sensitive biomarkers and novel therapies is reforming our approach to how we manage AL amyloidosis. Treatment for patients with AL amyloidosis should be risk-adapted and customized on the basis of individual patient characteristics. ...
Early referral to a specialized center with expertise in management of AL amyloidosis is always recommended. The availability of sens …
Acquired factor X deficiency in light-chain (AL) amyloidosis is rare and associated with advanced disease.
Patel G, et al. Hematol Oncol Stem Cell Ther 2019 - Clinical Trial. PMID 30879471 Free article.
INTRODUCTION: Systemic light chain (AL) amyloidosis can lead to an acquired coagulopathy secondary to acquired factor X (aFX) deficiency. However, it is not very clear who develops aFX deficiency in AL amyloidosis. METHODS: We therefore undertook this single centre, retrospective study to better characterize AL amyloidosis-associated aFX deficiency. ...
INTRODUCTION: Systemic light chain (AL) amyloidosis can lead to an acquired coagulopathy secondary to acquired factor X (aFX) deficie …
Mortality and healthcare costs in Medicare beneficiaries with AL amyloidosis.
Quock TP, et al. J Comp Eff Res 2018. PMID 30354284
AIMS: Examine mortality and healthcare costs in Medicare beneficiaries with newly diagnosed immunoglobulin light chain (AL) amyloidosis. ...CONCLUSION: Mortality was nearly four-times higher, and costs nearly five-times higher in beneficiaries with AL amyloidosis versus controls....
AIMS: Examine mortality and healthcare costs in Medicare beneficiaries with newly diagnosed immunoglobulin light chain (AL) amyloidosis
Presence of fluorescent in situ hybridization abnormalities is associated with plasma cell burden in light chain amyloidosis.
Hammons L, et al. Hematol Oncol Stem Cell Ther 2018 - Clinical Trial. PMID 28830801 Free article.
OBJECTIVE/BACKGROUND: To assess abnormalities found on CD138-enriched fluorescent in situ hybridization (FISH) studies on pre-treatment bone marrow in systemic amyloid light-chain amyloidosis (AL) and correlate findings between these abnormalities with organ involvement and 1-year survival. ...
OBJECTIVE/BACKGROUND: To assess abnormalities found on CD138-enriched fluorescent in situ hybridization (FISH) studies on pre-treatment bone …
Patient-reported distress is prevalent in systemic light chain (AL) amyloidosis but not determined by severity of disease.
Wright NL, et al. Amyloid 2018. PMID 30032653
We conducted this retrospective study to assess patient-reported distress in light chain (AL) amyloidosis, using the Distress Thermometer (DT) survey at first evaluation at our center. ...Distress in amyloidosis is not influenced by amyloid stage or type of organ involvement....
We conducted this retrospective study to assess patient-reported distress in light chain (AL) amyloidosis, using the Distress Thermom …
Rationale and design of DUAL study: Doxycycline to Upgrade response in light chain (AL) amyloidosis (DUAL): A phase 2 pilot study of a two-pronged approach of prolonged doxycycline with plasma cell-directed therapy in the treatment of AL amyloidosis.
D'Souza A, et al. Contemp Clin Trials Commun 2017. PMID 29696194 Free PMC article.
Light chain (AL) amyloidosis is a plasma cell neoplasm associated with insoluble fibril deposition from clonal immunoglobulin chains systemically. ...Pre-clinical and retrospective clinical data suggests that doxycycline has benefit in AL amyloidosis. The ongoing DUAL study is a single center, open label, phase 2 study in which patients with AL amyloidosis who are undergoing clone-directed therapy for the underlying neoplasm with oral doxycycline given for 1 year to test the hypothesis that prolonged doxycycline use will be safe, feasible, and lead to reduced early mortality in systemic AL amyloidosis and hasten organ amyloid response. ...
Light chain (AL) amyloidosis is a plasma cell neoplasm associated with insoluble fibril deposition from clonal immunoglobulin chains …
New Light Chain Amyloid Response Criteria Help Risk Stratification of Patients by Day 100 after Autologous Hematopoietic Cell Transplantation
D'Souza A, et al. Biol Blood Marrow Transplant 2016. PMID 26743343 Free PMC article.
Hematologic response criteria in light chain (AL) amyloidosis were updated in 2012 to incorporate free light chain responses. ...Using a transplantation registry, we assessed day 100 responses in AL amyloidosis. We validate the prognostic significance of the new criteria at this time point. ...
Hematologic response criteria in light chain (AL) amyloidosis were updated in 2012 to incorporate free light chain responses. ...Usin …
23 results
Jump to page
Feedback